2025-07-15T17:21:35-05:00 2025-04-30 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2025-01-01 812076517 INSTITUTE FOR ADVANCED CLINICAL TRIALS FOR CHILDREN INST 3016057571 11810 GRAND PARK AVENUE 500 NORTH BETHESDA MD 20852 ELIZABETH GAROFALO BOARD CHAIR 3016057571 2025-07-15 1 0 ELIZABETH W HELLER P00397829 3019519090 2024 2025-03-06 01:10:19Z X ELIZABETH GAROFALO 11810 GRAND PARK AVENUE 500 NORTH BETHESDA MD 20852 4060 0 X WWW.IACTC.ORG X 2016 DE SEE PART III, LINE 1. X 10 10 6 10 0 0 500972 0 96555 0 45177 3654 5814 406 648518 4060 528 191011 0 0 1820705 489878 7736 9729 187598 882097 616024 2711066 1306642 -2062548 -1302582 1381300 0 78718 0 1302582 0 X TO FUNCTION AS A NONPROFIT EDUCATIONAL, SCIENTIFIC AND RESEARCH ORGANIZATION TO ENABLE AND ADVANCE PEDIATRIC CLINICAL RESEARCH PRESCRIBED BY REGULATION THROUGH: (CONTINUED ON SCHED.O) 0 0 781422 191011 DURING THIS FIRST QUARTER OF 2025, THE ORGANIZATION RETURNED ANY PLEDGED FUNDS RECEIVED FROM MEMBERSHIP FEES AND EDUCATIONAL GRANTS.THE ORGANIZATION PROVIDES EXPERT GUIDANCE AND INPUT ON PEDIATRIC CLINICAL DEVELOPMENT PLANS AND PEDIATRIC CLINICAL TRIALS WITH THE GOAL OF IMPROVING THE PROCESSES AND ACCELERATING THE DEVELOPMENT OF INNOVATIVE PRODUCTS FOR USE IN CHILDREN. ADDITIONALLY, THE ORGANIZATION ALSO CONNECTS QUALIFIED CLINICAL TRIAL SITES IN OUR PEDIATRIC CLINICAL TRIAL SITE NETWORK WITH CLINICAL TRIALS FOR A VARIETY OF BIOPHARMACEUTICAL COMPANIES.THE ORGANIZATION UTILIZES ITS NETWORK OF EXPERTS TO CONVENE WORKING GROUPS TO TACKLE PROBLEMS IN PEDIATRIC CLINICAL DEVELOPMENT COMMON ACROSS A VARIETY OF STAKEHOLDERS, THAT OTHERWISE WOULD NOT BE ADDRESSED IN A PRECOMPETITIVE MANNER. 781422 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 8 0 1 6 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X LAURA LOPEZ 3016057571 11810 GRAND PARK AVENUE 500 NORTH BETHESDA MD 20852 ELIZABETH GAROFALO CHAIRWOMAN 3.00 X X 0 0 0 MARTHA BRUMFIELD SECRETARY/TREASURER 3.00 X X 0 0 0 BARRY BROOKS DIRECTOR 3.00 X 0 0 0 JAMES POMFRET DIRECTOR 3.00 X 0 0 0 MAX COPPES DIRECTOR 3.00 X 0 0 0 JEFF BARRETT DIRECTOR 3.00 X 0 0 0 DANIEL JORGENSEN DIRECTOR 3.00 X 0 0 0 TAMAROH LEWIS DIRECTOR 3.00 X 0 0 0 STEPHANIE DAVIS DIRECTOR 3.00 X 0 0 0 KRISTEN SWINGLE DIRECTOR 3.00 X 0 0 0 VIVIANNA GUZMAN EXECUTIVE DIRECTOR 40.00 X 147560 0 452 ALBERT JOHN ALLEN CMO (UNTIL 3/25) 10.00 X 22568 0 2554 LAURA LOPEZ CFAO 40.00 X 117309 0 8896 287437 0 11902 6 0 0 0 0 3654 3654 OTHER REVENUE 900099 406 406 406 4060 0 0 4060 191011 191011 173134 57171 63415 52548 264342 87304 96558 80480 1542 510 553 479 15233 3322 9489 2422 35627 11351 13808 10468 18554 11596 3479 3479 23499 12187 7656 3656 3001 1660 852 489 9729 9729 57314 31710 16271 9333 4989 624 3851 514 117642 15102 96213 6327 37749 8083 21992 7674 WRITE OFF OF MEMBERSHIP 250000 250000 WRITE OFF OF CONTRIBUTI 99791 99791 MISCELLANEOUS 2985 2985 OTHER SUBSCRIPTIONS 500 500 1306642 781422 337622 187598 536010 0 508820 0 0 250000 0 0 0 0 0 83485 0 0 0 0 0 0 0 0 2985 0 1381300 0 75391 3327 0 78718 0 X 752582 0 550000 0 1302582 0 1381300 0 -1302582 0 X 0 0 0 X 4045844 2354048 1126270 500972 8027134 4045844 2354048 1126270 500972 8027134 4230615 3796519 13051 19941 78674 45177 3654 160497 5814 406 6220 8193851 2512171 0.46330 0.48860 X PART II, SHORT YEAR EXPLANATION: 2025 TAX RETURN IS A SHORT YEAR END FOR THE PERIOD 1/1/25-4/30/25 DUE TO ORGANZATION BEING DISSOLVED. 0 3000 3000 1293913 1296913 204691 51173 0 0 314173 285167 204691 804031 1206047 36329 37484 3000 76813 78543 71292 51173 201008 301512 0 -345731 0 -345731 349791 349791 4060 956851 0 956851 349791 349791 1306642 PART XI, LINE 4B - OTHER ADJUSTMENTS: WRITE OFF OF CONTRIBUTIONS AND MEMBERSHIP FEES PART XII, LINE 4B - OTHER ADJUSTMENTS: WRITE OFF OF CONTRIBUTIONS AND MEMBERSHIP FEES 1 CRITICAL PATH INSTITUTE 1840 E RIVER ROAD STE 100 TUSCON AZ 85718 201991334 501(C)(3) 229392 0 GIFT AND GRANT AGREEMENT, EX B. ARTICLES OF DISSOLUTION. 1 0 PART I, LINE 2: I-ACT FOR CHILDREN MAINTAINS A PRE-QUALIFIED REGULATORY READY PEDIATRIC SITE NETWORK CONSISTING OF SITES IN THE UNITED STATES, AUSTRALIA, CENTRAL AND SOUTH AMERICA. I-ACT FOR CHILDREN'S INFRASTRUCTURE SUPPORTS A VARIETY OF PROGRAMS FOR CLINICAL TRIAL SITES. THESE PROGRAMS INCLUDE QUARTERLY INFORMATIONAL CALLS TO KEEP SITES UPDATED AND INFORMED ON THE LATEST DEVELOPMENTS IN PEDIATRIC RESEARCH, SITE STAFF EDUCATIONAL FORUMS (1 OCCURRED IN 2025), SITE STAFF EDUCATIONAL GRANT PROGRAMS, AND A YEARLY SITE STAFF AWARD. WE PROVIDE ASSISTANCE TO OUR SITES WITH NAVIGATING THE SHARED INVESTIGATOR PLATFORM (SIP), WHICH IS REQUIRED BY SOME SPONSORS FOR A SITE TO BE SELECTED AS AN INVESTIGATIONAL SITE. OUR SITE NETWORK STAFF ALSO PERFORM REGULAR ENGAGEMENT CALLS AND ON-SITE VISITS ENSURING ONGOING QUALITY, STAFFING, PROCESSES AND TO MITIGATE ANY ISSUES WHICH MAY BE DISCOVERED. ADDITIONALLY, I-ACT FOR CHILDREN MAINTAINS A SECURE NETWORK PORTAL TO ENHANCE COLLABORATION AND COMMUNICATION AMONG ITS MEMBERS. CASH 2025-04-29 229392 CASH 201991334 CRITICAL PATH INSTITUTE 1840 E RIVER ROAD STE 100 TUCSON AZ 85718 501(C)(3) 0 1 0 0 1 1 1 1 0 PART I, LINE 2E: PERSON(S) INVOLVED: LAURA LOPEZ PART I, LINE 2E: EXPLANATION OF INVOLVEMENT: CONTRACTED WITH CRITICAL PATH TO FACILITATE THE DISSOLUTION OF I-ACT FOR CHILDREN. FORM 990, PART III, LINE 1 CONTINUATION: (1) DEVELOPING, ADVANCING, ACCUMULATING AND MAINTAINING SCIENTIFIC DESCRIPTION OF ORGANIZATION MISSION: TO ESTABLISH AND DRIVE INNOVATION TO IMPROVE AND EXPEDITE PEDIATRIC DRUG DEVELOPMENT. OUR WORK IS NOT JUST ABOUT ADVANCING THE DEVELOPMENT OF NEW THERAPIES; IT'S ABOUT GIVING CHILDREN WITH MEDICAL CONDITIONS A BETTER CHANGE AT A HIGH QUALITY OF LIFE, ALLOWING THEM TO FLOURISH DESPITE THEIR CONDITION, WHICH FOR SOME, CAN BE A MATTER OF LIFE OF DEATH. ENGAGING SUBJECT MATTER EXPERTS, ACADEMICS, REGULATORY AGENCIES, DRUG DEVELOPERS AND PATIENT ADVOCATES IN OUR MISSION. TOGETHER, FOSTERING AN ENVIRONMENT THAT FINDS SOLUTIONS TO THE MANY CHALLENGES FOR SAFE AND EFFECTIVE PEDIATRIC DRUG DEVELOPMENT, AND (2) ENGAGING IN ANY LAWFUL ACT OR ACTIVITY FOR WHICH CORPORATIONS MAY BE ORGANIZED UNDER THE DELAWARE GENERAL CORPORATION LAW. AS AMENDED FROM TIME TO TIME. ALSO, TO ENGAGE IN ANY LAWFUL ACT OR ACTIVITY PERMITTED FOR ORGANIZATIONS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS THREE CLASSES OF MEMBERS (1) FOUNDING MEMBERS, CONSISTING OF CRITICAL PATH INSTITUTE, ELIZABETH GAROFALO, M.D., AND MARTHA BRUMFIELD, PH.D.; (2) SUSTAINING MEMBERS, CONSISTING OF ORGANIZATIONS THAT PROVIDE SUBSTANTIAL UNRESTRICTED FUNDS AS DUES TO THE CORPORATION OVER AN INITIAL MEMBERSHIP TERM OF FIVE YEARS, WITH ANNUAL CONTINUATION OPTION; AND (3) GENERAL MEMBERS, CONSISTING OF THOSE SUPPORTING THE PURPOSE AND ACTIVITIES OF THE CORPORATION OVER A ONE-YEAR TERM OF MEMBERSHIP. FORM 990, PART VI, SECTION A, LINE 7A FOUNDING AND SUSTAINING MEMBERS HAVE THE RIGHT TO VOTE ON THE BOARD OF DIRECTOR NOMINEES. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE AUDIT AND COMPENSATION COMMITTEE AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C TO ENSURE THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH CHARITABLE PURPOSES AND DOES NOT ENGAGE IN ACTIVITIES THAT COULD JEOPARDIZE TAX-EXEMPT STATUS, PERIODIC REVIEWS SHALL BE CONDUCTED. THE PERIODIC REVIEWS SHALL, AT A MINIMUM, INCLUDE THE FOLLOWING SUBJECTS: (1) WHETHER COMPENSATION ARRANGEMENTS AND BENEFITS ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION, AND THE RESULT OF ARM'S LENGTH BARGAINING, AND (2) WHETHER PARTNERSHIPS, JOINT VENTURES AND ARRANGEMENTS WITH MANAGEMENT ORGANIZATIONS CONFIRM TO THE CORPORATION'S WRITTEN POLICIES, ARE PROPERLY RECORDED, REFLECT REASONABLE INVESTMENT OR PAYMENTS FOR GOODS AND SERVICES, FURTHER CHARITABLE PURPOSE AND DO NOT RESULT IN INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT OR IN AN EXCESS BENEFIT TRANSACTION. WHEN CONDUCTING THE PERIODIC REVIEWS, THE ORGANIZATION MAY, BUT NEED NOT, USE OUTSIDE ADVISORS. IF OUTSIDE ADVISORS ARE USED, THEIR USE SHALL NOT RELIEVE THE GOVERNING BOARD OF ITS RESPONSIBILITY FOR ENSURING PERIODIC REVIEWS ARE CONDUCTED. FORM 990, PART VI, SECTION B, LINE 15 THE TOP MANAGEMENT OFFICIAL, EXECUTIVE DIRECTOR, HAS COMPENSATION REVIEWED BY AN INDEPENDENT PERSON (HR CONSULTANT AND AUDIT AND COMPENSATION COMMITTEE CHAIR, OR BOARD OF DIRECTORS APPOINTEE), COMPARABILITY DATA FROM BENCHMARKING AND DELIBERATION AND DECISION IS REFLECTED IN THE BOARD MEETING MINUTES. THE APPROVED PAY RATE UPON HIRE IS VALIDATED BY A SIGNED OFFER LETTER BY THE BOARD CHAIRPERSON FOR THE EXECUTIVE DIRECTOR. FOR THE CMO AND CFO POSITIONS, THE EXECUTIVE DIRECTOR, OR THE BOARD OF DIRECTORS CHAIRPERSON, WILL EVALUATE THE BENCHMARKING AND SIGN THE OFFER LETTER FOR THE APPROVED PAY RATE. FORM 990, PART VI, SECTION C, LINE 19 THE ARTICLES OF INCORPORATION, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.